Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 24
2003 26
2004 35
2005 33
2006 39
2007 23
2008 35
2009 29
2010 40
2011 19
2012 23
2013 25
2014 32
2015 27
2016 34
2017 31
2018 25
2019 28
2020 17
Text availability
Article attribute
Article type
Publication date

Search Results

497 results
Results by year
Filters applied: . Clear all
Page 1
Antibody-drug conjugates for cancer.
Chau CH, Steeg PS, Figg WD. Chau CH, et al. Among authors: Figg WD. Lancet. 2019 Aug 31;394(10200):793-804. doi: 10.1016/S0140-6736(19)31774-X. Lancet. 2019. PMID: 31478503 Review.
Thalidomide.
Franks ME, Macpherson GR, Figg WD. Franks ME, et al. Among authors: Figg WD. Lancet. 2004 May 29;363(9423):1802-11. doi: 10.1016/S0140-6736(04)16308-3. Lancet. 2004. PMID: 15172781 Review.
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
Szmulewitz RZ, Peer CJ, Ibraheem A, Martinez E, Kozloff MF, Carthon B, Harvey RD, Fishkin P, Yong WP, Chiong E, Nabhan C, Karrison T, Figg WD, Stadler WM, Ratain MJ. Szmulewitz RZ, et al. Among authors: Figg WD. J Clin Oncol. 2018 May 10;36(14):1389-1395. doi: 10.1200/JCO.2017.76.4381. Epub 2018 Mar 28. J Clin Oncol. 2018. PMID: 29590007 Free PMC article. Clinical Trial.
Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma.
Duffy AG, Ulahannan SV, Makorova-Rusher O, Rahma O, Wedemeyer H, Pratt D, Davis JL, Hughes MS, Heller T, ElGindi M, Uppala A, Korangy F, Kleiner DE, Figg WD, Venzon D, Steinberg SM, Venkatesan AM, Krishnasamy V, Abi-Jaoudeh N, Levy E, Wood BJ, Greten TF. Duffy AG, et al. Among authors: Figg WD. J Hepatol. 2017 Mar;66(3):545-551. doi: 10.1016/j.jhep.2016.10.029. Epub 2016 Nov 2. J Hepatol. 2017. PMID: 27816492 Free PMC article. Clinical Trial.
Antineoplastons: when is enough enough?
Figg WD. Figg WD. Lancet Oncol. 2018 Jun;19(6):733-734. doi: 10.1016/S1470-2045(18)30338-3. Epub 2018 Jun 1. Lancet Oncol. 2018. PMID: 29893248 No abstract available.
Reactive astrocytic S1P3 signaling modulates the blood-tumor barrier in brain metastases.
Gril B, Paranjape AN, Woditschka S, Hua E, Dolan EL, Hanson J, Wu X, Kloc W, Izycka-Swieszewska E, Duchnowska R, Pęksa R, Biernat W, Jassem J, Nayyar N, Brastianos PK, Hall OM, Peer CJ, Figg WD, Pauly GT, Robinson C, Difilippantonio S, Bialecki E, Metellus P, Schneider JP, Steeg PS. Gril B, et al. Among authors: Figg WD. Nat Commun. 2018 Jul 13;9(1):2705. doi: 10.1038/s41467-018-05030-w. Nat Commun. 2018. PMID: 30006619 Free PMC article.
Remission and Progression-Free Survival in Patients With Newly Diagnosed Multiple Myeloma Treated With Carfilzomib, Lenalidomide, and Dexamethasone: Five-Year Follow-up of a Phase 2 Clinical Trial.
Kazandjian D, Korde N, Mailankody S, Hill E, Figg WD, Roschewski M, Landgren O. Kazandjian D, et al. Among authors: Figg WD. JAMA Oncol. 2018 Dec 1;4(12):1781-1783. doi: 10.1001/jamaoncol.2018.5457. JAMA Oncol. 2018. PMID: 30477009 Free PMC article. Clinical Trial.
How do you take your coffee?
Sissung TM, Huang PA, Strope JD, Figg WD. Sissung TM, et al. Among authors: Figg WD. Lancet Oncol. 2019 Jul;20(7):913-914. doi: 10.1016/S1470-2045(19)30387-0. Lancet Oncol. 2019. PMID: 31267961 No abstract available.
A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1-3 inhibitor, cediranib, in recurrent women's cancers with biomarker analyses.
Zimmer AS, Nichols E, Cimino-Mathews A, Peer C, Cao L, Lee MJ, Kohn EC, Annunziata CM, Lipkowitz S, Trepel JB, Sharma R, Mikkilineni L, Gatti-Mays M, Figg WD, Houston ND, Lee JM. Zimmer AS, et al. Among authors: Figg WD. J Immunother Cancer. 2019 Jul 25;7(1):197. doi: 10.1186/s40425-019-0680-3. J Immunother Cancer. 2019. PMID: 31345267 Free PMC article.
497 results
Jump to page
Feedback